GlaxoSmithKline plc (LON:GSK) Declares Dividend of GBX 19

Share on StockTwits

GlaxoSmithKline plc (LON:GSK) announced a dividend on Wednesday, October 30th, Upcoming.Co.Uk reports. Investors of record on Thursday, November 14th will be given a dividend of GBX 19 ($0.25) per share on Thursday, January 9th. This represents a dividend yield of 1.07%. The ex-dividend date is Thursday, November 14th. The official announcement can be seen at this link.

Shares of GlaxoSmithKline stock traded up GBX 42.20 ($0.55) on Wednesday, hitting GBX 1,782 ($23.28). The company’s stock had a trading volume of 9,020,158 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 52-week low of GBX 1,408.80 ($18.41) and a 52-week high of GBX 1,770.60 ($23.14). The company has a quick ratio of 0.44, a current ratio of 0.71 and a debt-to-equity ratio of 1,127.74. The firm has a fifty day moving average price of GBX 1,683.65 and a 200-day moving average price of GBX 1,626.04. The company has a market capitalization of $88.90 billion and a P/E ratio of 20.07.

Several equities research analysts recently commented on GSK shares. Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a research report on Friday, August 23rd. Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 15th. Credit Suisse Group started coverage on shares of GlaxoSmithKline in a research report on Tuesday, October 1st. They issued a “neutral” rating and a GBX 1,700 ($22.21) price objective on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,850 ($24.17) price objective on shares of GlaxoSmithKline in a research report on Tuesday, October 15th. Finally, Kepler Capital Markets set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Tuesday, August 27th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of GBX 1,708.93 ($22.33).

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More: Can systematic risk be avoided?

Dividend History for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Snap Inc  CFO Derek Andersen Sells 8,194 Shares
Snap Inc CFO Derek Andersen Sells 8,194 Shares
Lawson Products, Inc.  Insider Manik Gupta Sells 3,444 Shares of Stock
Lawson Products, Inc. Insider Manik Gupta Sells 3,444 Shares of Stock
Nektar Therapeutics  Insider Jonathan Zalevsky Sells 3,960 Shares of Stock
Nektar Therapeutics Insider Jonathan Zalevsky Sells 3,960 Shares of Stock
FireEye Inc  EVP William T. Robbins Sells 6,256 Shares
FireEye Inc EVP William T. Robbins Sells 6,256 Shares
International Frontier Resources  Reaches New 12-Month Low at $0.02
International Frontier Resources Reaches New 12-Month Low at $0.02
Melkior Resources  Hits New 52-Week Low at $0.02
Melkior Resources Hits New 52-Week Low at $0.02


© 2006-2019 Ticker Report